profit from every $100 of sales.
$0$100
Pomdoctor
$1.62-2.41% today
-77.4% in 1 year
1-year low $0.531-year high $19.12
Trading close to its lowest price of the past year.
The essentials
Four questions every investor asks, answered in one line each.
more sales each year, on average, 2022 to 2025.
0%20% a year
It has no yearly profit to compare the price with.
CheapExpensive
of earnings would pay off all its debt.
No debt5 years
Money in, money out
What Pomdoctor sold, what it kept, and what it did with the cash.
Sales went from CN¥245 million in 2022 to CN¥400 million in 2025, with -CN¥213 million of profit last year.
SalesProfit
Pomdoctor vs. similar companies
How it compares with the largest companies in its industry.
| Company | Profit from $100 of sales | Sales growth a year | Price per $1 of profit |
|---|---|---|---|
| Pomdoctor | No profit yet | ||
 Atai Beckley N.V | No profit yet | ||
 Avalyn Pharma | No profit yet | ||
 Cullinan Therapeutics | No profit yet | ||
 High Tide | No profit yet |
AI analysis
An AI analyst reads Pomdoctor's last five years, its segments, earnings, insiders and peers, and writes the bull case, the bear case and what the price expects.
Run the AI analysisFull statementsIncome, balance sheet and cash flow, year by year
Income statement
| In millions of CNY | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| 245 | 305 | 343 | 400 | |
| 55 | 39 | 48 | 52 | |
| -3 | -20 | -23 | -116 | |
| -4 | -23 | -24 | -118 | |
| -126 | -145 | -143 | -213 | |
| -1.06 | -1.23 | -1.21 | -3.66 | |
| 22.4% | 12.7% | 13.9% | 13.1% | |
| -1.4% | -6.7% | -6.8% | -29.1% | |
| -51.2% | -47.7% | -41.9% | -53.2% |
Balance sheet
| In millions of CNY | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| Total assets | 49 | 66 | 46 | 108 |
| Cash | 2 | 7 | 8 | 10 |
| Total debt | 361 | 413 | 441 | 455 |
| Total liabilities | 1,947 | 2,028 | 2,141 | 589 |
| -1,975 | -2,120 | -2,263 | -454 | |
| 118 | 118 | 118 | 58 | |
| – | – | – | -9,627.7% | |
| 6.4% | 6.9% | 6.3% | 46.8% |
Cash flow
| In millions of CNY | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| -22 | -46 | -16 | -148 | |
| – | 0 | 0 | 1 | |
| -22 | -46 | -16 | -149 | |
| Dividends paid | – | – | – | – |
| – | – | – | – | |
| – | 0 | 0 | 16 |
Valuation
- –
- –
- –
- -0.0×
- 1.0×
- –
- –
- -38.5%
- -54.8%
- 0.0%
Profitability
- 13.1%
- -29.1%
- -53.2%
- -7.1%
- 44.0%
- 9.2%
- 6.5%
- -310.1%
- 19.4%
- 0.9%
Growth
- +17.7%
- –
- +64.8%
- –
- +0.0%
Financial health
- –
- -0.19
- 954.2%
- -2.0×
- 0.21
- 0.16
- 7.41
How it ranks in Healthcare
Each dot is where the company stands among every company over $300M in the sector. Further right is better.
Top 2%of 964
Bottom 9%of 898
Top 30%of 911
Bottom 1%of 991
News
No recent news on file.
Insider trades
Our insider feed has not updated since May 26, 2026. Trades filed after that are not listed yet.
No insider trades on file.
The seven classic investing rulebooks
1/7Passes 1 of 7. Each bar is how well the company fits that investor's published rules, from 0 to 100; 60 or more counts as a pass.
Warren Buffett
17No pass
Benjamin Graham
2No pass
Philip Fisher
36No pass
Peter Lynch
44No pass
Joel Greenblatt
60Pass
Charlie Munger
25No pass
Terry Smith
27No pass
Questions about Pomdoctor
Is Pomdoctor a good stock to buy?
A business with weak numbers that is not profitable yet. 1 of the 7 famous investors' published rulebooks we apply pass it. Whether it suits you depends on your goals and the price you pay; invest-like never tells anyone to buy or sell. The AI analysis lays out the case for and against. Read the Pomdoctor AI analysis
What does Pomdoctor do?
Pomdoctor Limited, through its subsidiaries, offers an online B2C portal to sell pharmaceutical products. The company develops an online medical services platform for chronic diseases in China. It is in Medical - Pharmaceuticals.
Does Pomdoctor pay a dividend?
No. Pomdoctor does not pay a dividend at the moment.
Is Pomdoctor stock halal?
No. Pomdoctor does not pass our halal screen: its debt is 117% of its market value, at or above the 33% limit. How we check
How has Pomdoctor stock done over the past year?
Down 77.4% over the past twelve months, to $1.62. It traded between $0.53 and $19.12 and is 91.5% below its high.
Who are Pomdoctor's competitors?
The largest listed companies in the same industry are Atai Beckley N.V, Avalyn Pharma, Cullinan Therapeutics and High Tide. The peers table on this page compares their profit, growth and price with Pomdoctor's.
Prices: daily closes to Nov 13, 2026. Fundamentals: company reports via invest-like data.